Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030001, China.
Southern University of Science & Technology, Shenzhen, 518000, China.
Future Oncol. 2023 Sep;19(30):2055-2073. doi: 10.2217/fon-2023-0227. Epub 2023 Oct 12.
Androgen deprivation therapy is a common treatment method for metastatic prostate cancer through lowering androgen levels; however, this therapy frequently leads to the development of castration-resistant prostate cancer (CRPC). This is attributed to the activation of the androgen receptor (AR) signaling pathway. Current treatments targeting AR are often ineffective mostly due to gene overexpression and mutations, as well as the presence of splice variants that accelerate CRPC progression. Thus there is a critical need for more specific medication to treat CRPC. Small interfering RNAs have shown great potential as a targeted therapy. This review discusses prostate cancer progression and the role of AR signaling in CRPC, and proposes siRNA-based targeted therapy as a promising strategy for CRPC.
雄激素剥夺疗法是治疗转移性前列腺癌的常用方法，通过降低雄激素水平；然而，这种疗法常常导致去势抵抗性前列腺癌（CRPC）的发展。这归因于雄激素受体（AR）信号通路的激活。目前针对 AR 的治疗方法通常无效，主要是由于基因过表达和突变，以及剪接变异体的存在加速了 CRPC 的进展。因此，迫切需要更特异的药物来治疗 CRPC。小干扰 RNA 已显示出作为靶向治疗的巨大潜力。本文讨论了前列腺癌的进展以及 AR 信号在 CRPC 中的作用，并提出了基于 siRNA 的靶向治疗作为 CRPC 的一种有前途的策略。
